La Jolla, CA, October 24, 2023 (Business Wire) -- Rampart Bioscience, Inc., a biotechnology firm dedicated to the advancement of next-generation announces an $85 million Series A financing. It is focused on medical solutions that alleviate the burdens imposed by disease and conventional treatments.
Read full article here.
Durham, NCÂ and Seattle, WA, January 12, 2025 (Business Wire) -- Tune Therapeutics has raised $175 million in Series B funding to...
Ribometrix Names William S. Marshall, Ph.D., as CEO to Drive Breakthrough RNA-Targeting Therapeutics
Durham, NC, January 09, 2025 (Globe newswire) -- Ribometrix has appointed Dr. William S. Marshall as CEO and Dr. Katie Warner as CSO,...
San Francisco & Princeton, NJ, January 10, 2025 (Business Wire) -- Kardigan launches with $300 million in funding and a mission to cure...
Commentaires